ArticleMolecules (Basel, Switzerland)2021
Nanoformulation and Evaluation of Oral Berberine-Loaded Liposomes.
Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Research on the Mechanism of Natural Products Acting on Chronic Obstructive Pulmonary Disease.Food science & nutrition · 2026Review
- Curcumin-piperine liposomal hydrogel formulation for topical management of atopic dermatitis and associated skin inflammation: optimization, in vitro and in vivo studies.Inflammopharmacology · 2026Article
- Berberine in oral diseases: molecular mechanisms and therapeutic implications.Frontiers in pharmacology · 2026Review
- Integrating the Wei-Qi-Ying-Blood Theory with Modern Pathophysiology: A Multitarget Translational Framework for Dengue Management.International journal of general medicine · 2026Review
- Liposome integrated hydrogel for diabetic wound healing: molecular mechanisms in inflammation and oxidative stress mitigation.Inflammopharmacology · 2025Article
- Overcoming Bioavailability Barriers: Optimized Hybrid Nanocarrier System to Amplify Berberine Absorption via Peyer's Patches.AAPS PharmSciTech · 2025Article
- Sterilization Effects on Liposomes with Varying Lipid Chains.Nanomaterials (Basel, Switzerland) · 2025Article
- Antiviral Activity of Liposomes Containing Natural Compounds Against CHIKV.Pharmaceutics · 2025Article
- The delivery carriers and applications for Xiaobojian.Discover nano · 2025Review
- Alkaloid Extraction fromMolecules (Basel, Switzerland) · 2025Article
- Imidacloprid exposure in rats induces cardiac inflammatory response through activating TLR4/NF-κB/NLRP3 and JAK/STAT signaling pathways: focus on the berberine-loaded nanoliposomes.Frontiers in toxicology · 2025Article
- A Novel Delivery System for the Combined Use of Natural Ingredients: The Preparation of Berberine Hydrochloride-Matrine Liposomes and Preliminary Exploration of Their Anti-Tumor Activity.Molecules (Basel, Switzerland) · 2024Article
- Enhancement of the stability and cytotoxicity of berberine by liposomal nanocarriers for gastric cancer treatment and its application in gummy candy.Frontiers in gastroenterology (Lausanne, Switzerland) · 2024Article
- Fluorescent liposomal nanocarriers for targeted drug delivery in ischemic stroke therapy.Biomaterials science · 2023Article
- Characterization and Pharmacokinetic Assessment of a New Berberine Formulation with Enhanced Absorption In Vitro and in Human Volunteers.Pharmaceutics · 2023Article
- Lipid-hybrid cell-derived biomimetic functional materials: A state-of-the-art multifunctional weapon against tumors.Materials today. Bio · 2023Review
- Preparation of Uniform Nano Liposomes Using Focused Ultrasonic Technology.Nanomaterials (Basel, Switzerland) · 2023Article
- Enhanced drug delivery and wound healing potential of berberine-loaded chitosan-alginate nanocomposite gel: characterization andFrontiers in public health · 2023Article
- Strategies for Solubility and Bioavailability Enhancement and Toxicity Reduction of Norcantharidin.Molecules (Basel, Switzerland) · 2022Review
- RecapsomaLife (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Berberine (BBR) is a poorly water-soluble quaternary isoquinoline alkaloid of plant origin with potential uses in the drug therapy of hypercholesterolemia. To tackle the limitations associated with the oral therapeutic use of BBR (such as a first-pass metabolism and poor absorption), BBR-loaded liposomes were fabricated by ethanol-injection and thin-film hydration methods. The size and size distribution, polydispersity index (PDI), solid-state properties, entrapment efficiency (EE) and in vitro drug release of liposomes were investigated. The BBR-loaded liposomes prepared by ethanol-injection and thin-film hydration methods presented an average liposome size ranging from 50 nm to 244 nm and from 111 nm to 449 nm, respectively. The PDI values for the liposomes were less than 0.3, suggesting a narrow size distribution. The EE of liposomes ranged from 56% to 92%. Poorly water-soluble BBR was found to accumulate in the bi-layered phospholipid membrane of the liposomes prepared by the thin-film hydration method. The BBR-loaded liposomes generated by both nanofabrication methods presented extended drug release behavior in vitro. In conclusion, both ethanol-injection and thin-film hydration nanofabrication methods are feasible for generating BBR-loaded oral liposomes with a uniform size, high EE and modified drug release behavior in vitro.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.